SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in
December 2019. Vaccines developed were very effective initially, however, the virus has …

SARS-CoV-2 continues to accumulate mutations to evade immunity, leading to
breakthrough infections after vaccination. How researchers can anticipate the evolutionary …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …

Abstracts Despite the rising natural and vaccines mediated immunity, several countries have
experienced a resurgence of the Coronavirus disease of 2019 (COVID-19) due to the …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the …

Abstract The coronavirus disease 2019 (COVID‐19) pandemic can hardly end with the
emergence of different variants over time. In the past 2 years, several variants of severe …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had
become a global concern because of its unexpectedly high pathogenicity and …

The emergence and rapid spread of SARS-CoV-2 variants may affect vaccine efficacy
substantially. The Omicron variant termed BA. 2, which differs substantially from BA. 1 based …

SARS-CoV-2 can mutate to evade immunity, with consequences for the efficacy of emerging
vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant …

Since the worldwide emergence of the COVID-19 outbreak, there have been international
concerns about the possible viral evolution into variants with underlying mutations that may …